Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer
European Journal of Cancer · 2024-10 · 210 · 114257
DOI: 10.1016/j.ejca.2024.114257 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2024-10. Verfasst von Si-Yang Liu und 32 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, NY, USA; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Acad…. Hauptthemen laut MEDLINE: Lung Neoplasms, Circulating Tumor DNA, Erb-b2 Receptor Tyrosine Kinases, Mutation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, National Institutes of Health.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center, New York, NY, USA; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Chinese Thoracic Oncology Group, Guangzhou, C…
- Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medicine, Cornell University, New York, NY, USA.
- Resolution Bioscience, Exact Sciences, Kirkland, WA, USA.
- Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medicine, Cornell University, New York, NY, USA. Electronic address: lib1@mskcc.org.
Förderung
- NCI NIH HHS
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Liu, S. Y., Erazo, T., Jee, J., Arfe, A., Gupta, A., Pike, L. R. G., Santini, F. C., Daly, B., Schoenfeld, A., Eichholz, J., Johnson, K., Martinez, A., Sui, J., Riaz, N., Chang, J., Yang, S. R., Travis, W., Arcila, M. E., Guo, J., …, & Li, B. T. (2024). Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer. European Journal of Cancer, 210, 114257. https://doi.org/10.1016/j.ejca.2024.114257
Vancouver
Liu SY, Erazo T, Jee J, Arfe A, Gupta A, Pike LRG, et al. Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer. European Journal of Cancer. 2024;210:114257. doi:10.1016/j.ejca.2024.114257
BibTeX
@article{Liu2024,
author = {Liu, Si-Yang and Erazo, Tatiana and Jee, Justin and Arfe, Andrea and Gupta, Avantika and Pike, Luke R G and Santini, Fernando C and Daly, Bobby and Schoenfeld, Adam and Eichholz, Jordan and Johnson, Kaylie and Martinez, Andres and Sui, Jane and Riaz, Nadeem and Chang, Jason and Yang, Soo-Ryum and Travis, William and Arcila, Maria E and Guo, Jiannan and Gagne, Eric and Garg, Kavita and Baehner, Frederick and Lee, Nancy Y and Drilon, Alexander and Kris, Mark G and Scher, Howard I and Razavi, Pedram and Gomez, Daniel R and Jones, David R and Rudin, Charles M and Chandarlapaty, Sarat and Isbell, James M and Li, Bob T},
title = {Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer},
journal = {European Journal of Cancer},
year = {2024},
volume = {210},
pages = {114257},
doi = {10.1016/j.ejca.2024.114257}
}
EUVIMED